Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis
article has not abstract
Vyšlo v časopise:
Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for Tuberculosis. PLoS Med 8(7): e32767. doi:10.1371/journal.pmed.1001063
Kategorie:
Essay
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001063
Souhrn
article has not abstract
Zdroje
1. PaiMMinionJSteingartKRamsayA 2010 New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16 271 284
2. World Health Organization 2010 Framework for implementing new tuberculosis diagnostics Geneva WHO Available: http://www.who.int/tb/laboratory/whopolicyframework_july10_revnov10.pdf. Accessed 24 June 2011
3. BoehmeCCNabetaPHillemannDNicolMPShenaiS 2010 Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363 1005 1015
4. BoehmeCCNicolMPNabetaPMichaelJSGotuzzoE 2011 Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377 1495 1505
5. World Health Organization 2010 WHO endorses new rapid tuberculosis test. Available: http://www.who.int/tb/features_archive/new_rapid_test/en/. Accessed 13 March 2011
6. Foundation for Innovative New Diagnostics 2010 FIND Negotiated Priced for Xpert MTB/RIF and Country List. Available: http://www.finddiagnostics.org/programs/tb/find-negotiated-prices/xpert_mtb_rif.html. Accessed 7 March 2011
7. RussellLBGoldMRSiegelJEDanielsNWeinsteinMC 1996 The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA 276 1172 1177
8. DowdyDWLourençoMCCavalcanteSCSaraceniVKingB 2008 Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS ONE 3 e4057
9. Acuna-VillaordunaCVassallAHenostrozaGSeasCGuerraH 2008 Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis 47 487 495
10. DowdyDWO'BrienMABishaiD 2008 Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 12 1021 1029
11. Commission on Macroeconomics and Health 2001 Macroeconomics and health: investing in health for economic development Geneva World Health Organization
12. SchererLCSperhackeRDRuffino-NettoARossettiMLVaterC 2009 Cost-effectiveness analysis of PCR for the rapid diagnosis of pulmonary tuberculosis. BMC Infect Dis 9 216
13. BasingaPMoreiraJBisoffiZBisigBVan den EndeJ 2007 Why are clinicians reluctant to treat smear-negative tuberculosis? An inquiry about treatment thresholds in Rwanda. Med Decis Making 27 53 60
14. DinnesJDeeksJKunstHGibsonACumminsE 2007 A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 11 1 196
15. LingDIFloresLLRileyLWPaiM 2008 Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS ONE 3 e1536
16. PaukerSGKassirerJP 1980 The threshold approach to clinical decision making. N Engl J Med 302 1109 1117
17. DavisJLKatambaAVasquezJCrawfordESSerwangaA 2011 Evaluating Tuberculosis Case Detection via Real-time Monitoring of Tuberculosis Diagnostic Services. Am J Respir Crit Care Med In press
18. BaltussenRFloydKDyeC 2005 Cost effectiveness analysis of strategies for tuberculosis control in developing countries. BMJ 331 1364
19. Central Intelligence Agency 2010 CIA world factbook. CIA: Washington (D.C.). Available: https://www.cia.gov/library/publications/the-world-factbook. Accessed 25 March 2011
20. SchünemannHJOxmanADBrozekJGlasziouPJaeschkeR 2008 Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 1106 1110
21. MannGSquireSBBissellKEliseevPDu ToitE 2010 Beyond accuracy: creating a comprehensive evidence base for TB diagnostic tools. Int J Tuberc Lung Dis 14 1518 1524
22. MoreiraJBisigBMuwawenimanaPBasingaPBisoffiZ 2009 Weighing harm in therapeutic decisions of smear-negative pulmonary tuberculosis. Med Decis Making 29 380 390
23. MoultonLHGolubJEDurovniBCavalcanteSCPachecoAG 2007 Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials 4 190 199
24. FriedenTR 2009 Lessons from tuberculosis control for public health. Int J Tuberc Lung Dis 13 421 428
25. BishaiD 2009 Cost-effectiveness of screening for tuberculosis. Available: http://www.tbtools.org/. Accessed 14 March 2011
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 7
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Zástava srdce u pacienta se střelnými ranami – kazuistika
- Statinová intolerance
Najčítanejšie v tomto čísle
- Individualized Cost-Effectiveness Analysis
- GeneXpert—A Game-Changer for Tuberculosis Control?
- Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study
- Treatment Outcomes and Cost-Effectiveness of Shifting Management of Stable ART Patients to Nurses in South Africa: An Observational Cohort